Prophylaxis with Septran DS in Children

Dosage and Administration

The Centers for Disease Control and Prevention recommends a prophylactic dose of 8 mg/kg/day of the trimethoprim component, divided into two doses, for children, which for a 16kg child equals 128 mg of trimethoprim per day 1
The prophylactic regimen can be administered three consecutive days per week, as an alternative to daily administration, for certain indications 1

The Centers for Disease Control and Prevention recommends trimethoprim-sulfamethoxazole for Pneumocystis jiroveci pneumonia (PCP) prophylaxis in immunocompromised children 1
Post-exposure prophylaxis for certain infections can be done with trimethoprim-sulfamethoxazole, though it is an alternative, not first-line agent, as recommended by the Centers for Disease Control and Prevention 2, 3
Regular monitoring, including complete blood counts with differential and platelet count, should be performed at initiation of TMP-SMX prophylaxis and monthly thereafter to assess for hematologic toxicity, as recommended by the Centers for Disease Control and Prevention 1

For a 16kg child, liquid formulation may be more appropriate for accurate dosing, according to the British National Formulary 4

Common side effects of trimethoprim-sulfamethoxazole include rash, gastrointestinal disturbances, and hematologic abnormalities, as reported by the Centers for Disease Control and Prevention 1
If life-threatening toxicity occurs, the drug should be permanently discontinued, as recommended by the Centers for Disease Control and Prevention 1

The Centers for Disease Control and Prevention (CDC) recommends a standard dose of 150 mg/m²/day of trimethoprim with 750 mg/m²/day of sulfamethoxazole, divided into two doses and given three consecutive days per week for PCP prophylaxis in immunocompromised children 5, 6
The CDC recommends three consecutive days per week as the preferred prophylactic schedule, though several alternatives exist, including daily administration, three times weekly on alternate days 5, 6

For HIV-infected children requiring PCP prophylaxis, the CDC recommends prophylaxis for infants 1-12 months, children 1-5 years with CD4+ count <500/μL or CD4+ percentage <15%, and children 6-12 years with CD4+ count <200/μL or CD4+ percentage <15% 6

If trimethoprim-sulfamethoxazole is contraindicated or not tolerated, alternative agents include dapsone (children >1 month): 2 mg/kg daily (max 100 mg) or 4 mg/kg weekly (max 200 mg), aerosolized pentamidine (children >5 years): 300 mg monthly via Respirgard II nebulizer, and atovaquone: Age-based dosing (1-3 months and >24 months: 30 mg/kg daily; 4-24 months: 45 mg/kg daily) 5, 6

The Centers for Disease Control and Prevention (CDC) recommends that all HIV-infected or HIV-exposed infants should receive trimethoprim-sulfamethoxazole (TMP-SMX, cotrimoxazole) prophylaxis starting at 4-6 weeks of age, with the preferred regimen being 150 mg TMP/750 mg SMX per m² body surface area per day, divided into two doses and administered three consecutive days per week 7
For HIV-exposed infants, prophylaxis should be begun at 4-6 weeks of age and continued throughout the first year of life until HIV infection is definitively ruled out, according to the CDC 8, 9
The American Academy of Pediatrics and CDC recommend that age-specific CD4+ thresholds determine continuation of prophylaxis in confirmed HIV-infected children, with all HIV-infected infants requiring prophylaxis regardless of CD4+ count 7

When TMP-SMX cannot be tolerated or is contraindicated, alternative prophylactic agents such as dapsone, atovaquone, and aerosolized pentamidine may be used, with specific dosing regimens and strength of recommendations provided by the CDC 7
The CDC recommends monitoring for adverse effects, including rash, gastrointestinal disturbances, and hematologic abnormalities, with approximately 15% of HIV-infected children experiencing substantial adverse reactions 10

Children with a history of Pneumocystis jirovecii pneumonia must receive lifelong secondary prophylaxis to prevent recurrence, using the same regimens as primary prophylaxis, with a strength of recommendation of AI from the CDC 7, 11
Discontinuation criteria include confirmation of HIV-negative status in HIV-exposed infants and consideration of discontinuation in HIV-infected children if CD4+ counts rise above age-specific thresholds on two sequential measurements at least 1 month apart in the context of effective antiretroviral therapy 8, 9